Select Conferences

Hollis-Eden Commences Phase I/II Clinical Trial with TRIOLEX™ in Rheumatoid Arthritis Patients
The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of TRIOLEX when administered orally for 28 days at three different dose levels.

Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study in healthy volunteers.

BioFocus DPI Transfers Predictive Drug Discovery Databases to European Bioinformatics Institute
Wellcome Trust grant makes the data publicly available on-line to drug discovery researchers worldwide through the EMBL-EBI.

Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone
The expanded library significantly enhances Telik's patented drug discovery technology, Target Related Affinity Profiling.

Compound Libraries 2008: Design – Synthesis – Hit-to-lead optimization, Düsseldorf, Germany
06 October 2008 - 08 October 2008

Presentations will cover the design and enhancement of different kinds of libraries as well as the possibilities of hit-to-lead optimization. Experts from companies such as Pfizer, AstraZeneca, Merck, Grünenthal, Sanofi-Aventis will report about first-hand experiences and best practices.

Second International Symposium on Combinatorial Sciences, Beijing, China
19 September 2009 - 22 September 2009

The Second International Symposium on Combinatorial Sciences in Biology, Chemistry, Catalysts and Materials (SCS-09) will feature plenary lectures from: Jim Wells, University of California, San Francisco ;Jon Ellman, University of California, Berkeley; Dennis Curran, University of Pittsburgh, U.S.A.

Quality Systems Co-ordinator
Select Biosciences Recruitment
UK

Process Development Manager
Select Biosciences Recruitment
UK

Research Scientist
Select Biosciences Recruitment
UK

Use of Nucleofector® Technology to Establish Stably Expressing Cell Lines
Amaxa GMBH

The number of stably expressing clones resulting from standard transfection experiments is often quite low, especially for cells which are difficult to transfect. This limits many research applications. We show here that the Nucleofector® Technology can successfully be used to generate stably expressing clones at high efficiency. Although a general protocol cannot be given, the data shown here can serve as a guideline for fast establishment of stable transfection protocols for various cell lines

Efficient Delivery of Dharmacon SMARTpool siRNA Reagents in Hard-To-Transfect Cell Lines Using amaxa Nucleofector® 96-well Shuttle® System
Amaxa GMBH

In this Technical Note, Dharmacon and amaxa technologies were applied to Jurkat cells with the aim of performing future siRNA library screens. Jurkat cells are derived from a human acute T-cell leukemia line and are used extensively in the study of T cell signaling and cancer drug development. As with any suspension cell line, Jurkat cells are hard to transfect using reagentmediated delivery.
  

Automated High Throughput Nucleofection®
Bayer Schering Pharma AG, amaxa AG, Tecan AG

Using primary cells for RNAi based applications such as target identification or – validation, requires a highly efficient transfection technology in combination with a reliable and robust automation system. To accomplish these requirements we integrated the amaxa 96-well Shuttle® in a Tecan Freedom EVO® cell transfection workstation which is based on Tecan’s Freedom EVO® liquid handling platform and include all the necessary components and features for unattended cell transfection.

High Throughput Surface Tension Measurement
University of Liverpool, Centre for Materials Discovery

Understanding the surface tension properties of aqueous surfactants and polymer materials is important for the pharmaceutical, coatings, paints, inks, surfactant and household products industries. The traditional methods of measuring surface tension are tedious and time-consuming, so only a few compounds can be measured by a single user per day.